Skip to main content
. 2016 Feb 26;7(14):18876–18886. doi: 10.18632/oncotarget.7739

Figure 2. NSCLC adenocarcinoma patients' genetic alterations detected by NGS.

Figure 2

In all the patient samples tested, 23.3% of EGFR, 32.5% of KRAS, 7.5% of ALK, 0.8% of ROS1, 1.7% of RAF1, 10.8% of RET, 4.2% of ERBB2, 10.0% of PIK3CA, 5.0% of MET, 6.7% of CBL, and 12.5% of BRAF alteration were detected.